Back to Journals » Patient Preference and Adherence » Volume 10

Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain

Authors Nolla J, Rodríguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, Aragon B, Lizan L, Prades M, Martinez E

Received 12 February 2016

Accepted for publication 11 May 2016

Published 20 June 2016 Volume 2016:10 Pages 1101—1113


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Joan M Nolla,1 Manuel Rodríguez,2 Emilio Martin-Mola,3 Enrique Raya,4 Isabel Ibero,5 Gonzalo Nocea,6 Belén Aragon,6 Luis Lizán,7 Miriam Prades7

1Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain; 2Department of Rheumatology, Complejo Hospitalario de Ourense, Ourense, Spain; 3Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain; 4Department of Rheumatology, Hospital Universitario San Cecilio, Granada, Spain; 5Hospital General de Elda, Alicante, Spain; 6Outcomes Research, MSD, Madrid, Spain; 7Outcomes’10, Castellón, Spain

Purpose: To define importance values assigned to attributes of biological agents (BAs) by Spanish patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and rheumatologists.
Patients and methods: This was an observational, cross-sectional design based upon a rank-based full-profile conjoint analysis. A literature review and four focus groups were undertaken to identify attributes and levels. An orthogonal matrix, combining the selected levels of attributes, was used to define scenarios. Participants ranked eight scenarios from 1 (most preferred) to 8 (least preferred). The relative importance (RI) of attributes was calculated. Multivariate regression analysis was performed to identify the characteristics that influenced the values of RI. A total of 488 patients (male 50.9%, mean age 50.6 [standard deviation {SD} 12.06] years, rheumatoid arthritis 33.8%, ankylosing spondylitis 32.4%, psoriatic arthritis 33.8%; mean time since diagnosis 12.6 [SD 8.2] years) and 136 rheumatologists (male 50.4%, mean age 46.4 [SD 9.1] years, mean time of practice 16.7 [SD 8.8] years) participated.
Results: The ideal BAs for patients and physicians, respectively, should allow pain relief and improvement of functional capacity (RI 39% and 44.7%), with low risk of adverse events (RI 24.9% and 30.5%), a long time prior to perceiving the need for a new dose (RI 16.4% and 12.4%), and self-administration at home (RI 19.7% and 12.5%), as identified through their preferences.
Conclusion: Although efficacy and safety are paramount for patients and rheumatologists to make a choice regarding BAs, the need for a low frequency of administration and the administration method also play a role as preference attributes for BAs.

Keywords: preferences, conjoint analysis, attributes, biological agents, rheumatic diseases

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]